Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 9:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 7,362 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: NERVES Clear all
Completed No phase listed Observational Accepts healthy volunteers

Diagnosis and Treatment of Pheochromocytoma

NCT00001229
View directory record Official record
Conditions
Pheochromocytoma
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1988 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 28, 2026, 9:46 AM EDT
Active, not recruiting Phase 2 Interventional

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

NCT04305145
View directory record Official record
Conditions
Melanoma Stage III, Melanoma Stage IV, Skin Cancer Stage III, Skin Cancer Stage IV, Drug-Induced Colitis, Drug Toxicity, Immune-related Adverse Event
Interventions
Infliximab, Methylprednisolone, Prednisone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 28, 2026, 9:46 AM EDT
Completed Phase 1 Interventional

Safety Study of TPI-287 to Treat CBS and PSP

NCT02133846
View directory record Official record
Conditions
Primary Four Repeat Tauopathies (4RT), Corticobasal Syndrome (CBS), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
Interventions
TPI 287 2 mg/m2, TPI-287 20 mg/m2, Placebo, TPI-287 6.3 mg/m2
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Birmingham, Alabama • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Oct 28, 2026, 9:46 AM EDT
Completed Phase 1 Interventional

Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme

NCT01934361
View directory record Official record
Conditions
Recurrent Glioblastoma Multiforme
Interventions
buparlisib, carboplatin, lomustine, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 28, 2026, 9:46 AM EDT
Completed No phase listed Observational

A New View of Normal Tension Glaucoma: Autoregulation and Systemic Blood Pressure

NCT00706056
View directory record Official record
Conditions
Normal Tension Glaucoma
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years to 101 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 28, 2026, 9:46 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor

NCT07549022
View directory record Official record
Conditions
Malignant Peripheral Nerve Sheath Tumors, MPNST
Interventions
BMS-986504
Drug
Lead sponsor
Ankit Mangla, MD
Other
Eligibility
12 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 28, 2026, 9:46 AM EDT
Terminated No phase listed Observational

Comparison of Contrast Agents for MRI Perfusion Analysis in Brain Tumor Patients

NCT02095353
View directory record Official record
Conditions
Central Nervous System Neoplasms
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 28, 2026, 9:46 AM EDT
Withdrawn Phase 1Phase 2 Interventional

A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors

NCT04614766
View directory record Official record
Conditions
Gastro-enteropancreatic Neuroendocrine Tumor, Neuroendocrine Tumors
Interventions
Lutathera, Azedra
Drug
Lead sponsor
David Bushnell
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Oct 28, 2026, 9:46 AM EDT
Suspended Phase 2 Interventional

Autologous Incubated Macrophages for Patients With Complete Spinal Cord Injuries

NCT00073853
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Autologous Incubated Macrophages (cell therapy)
Procedure
Lead sponsor
Proneuron Biotechnologies
Industry
Eligibility
16 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
6
States / cities
Englewood, Colorado • Atlanta, Georgia • Newark, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2009 · Synced Oct 28, 2026, 9:46 AM EDT
Completed Phase 2 Interventional Results available

Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab

NCT04401995
View directory record Official record
Conditions
Melanoma
Interventions
Vidutolimod (CMP-001), Nivolumab, [18F]F-AraG PET/CT
Drug · Biological · Other
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 28, 2026, 9:46 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Radiosurgery for Glioblastoma Multiforme

NCT00456612
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
CyberKnife
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
66 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 28, 2026, 9:46 AM EDT
Withdrawn No phase listed Observational

Autonomic Phenotype Before and After Akt Inhibition

NCT01593579
View directory record Official record
Conditions
Diagnosis of Melanoma
Interventions
Autonomic Function Tests, supine and standing catecholamines
Behavioral · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 28, 2026, 9:46 AM EDT
Active, not recruiting Phase 2 Interventional

Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease (Protocol 53136)

NCT03775096
View directory record Official record
Conditions
REM Sleep Behavior Disorder, Pre-motor Parkinson Disease, Symptomatic Parkinson Disease
Interventions
Carvedilol
Drug
Lead sponsor
Michele Tagliati, MD
Other
Eligibility
50 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 28, 2026, 9:46 AM EDT
Terminated Phase 1Phase 2 Interventional

Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma

NCT00945269
View directory record Official record
Conditions
Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma
Interventions
therapeutic autologous lymphocytes, aldesleukin, denileukin diftitox, biopsy, immunohistochemistry staining method, laboratory biomarker analysis, polymerase chain reaction
Biological · Procedure · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Oct 28, 2026, 9:46 AM EDT
Terminated Phase 2 Interventional Results available

Study of Panobinostat in Patients With Neuroendocrine Tumors

NCT00985946
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
panobinostat (LBH589)
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 28, 2026, 9:46 AM EDT
Completed Phase 1 Interventional

R(+)XK469 in Treating Patients With Advanced Neuroblastoma

NCT00028522
View directory record Official record
Conditions
Disseminated Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma
Interventions
R(+)XK469
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
5 Years to 20 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Oct 28, 2026, 9:46 AM EDT
Active, not recruiting Phase 1 Interventional

Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma

NCT01711554
View directory record Official record
Conditions
Recurrent Neuroblastoma, Refractory Neuroblastoma
Interventions
Dinutuximab, Isotretinoin, Laboratory Biomarker Analysis, Lenalidomide, Pharmacological Study
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
14
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 28, 2026, 9:46 AM EDT
Active, not recruiting No phase listed Observational

Multi-parametric Biomarker Development to Predict Malignant Conversion in Patients With Neurofibromatosis Type 1

NCT05677594
View directory record Official record
Conditions
Neurofibromatosis 1, Malignant Peripheral Nerve Sheath Tumor (MPNST) of Soft Tissue (Diagnosis), Atypical Neurofibroma
Interventions
Whole Body Magnetic Resonance Imaging
Diagnostic Test
Lead sponsor
Johns Hopkins University
Other
Eligibility
6 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 28, 2026, 9:46 AM EDT
Completed No phase listed Observational

Validating Pain Scales in Children and Young Adults

NCT01639950
View directory record Official record
Conditions
Sickle Cell Disease, Solid Tumor, Leukemia, Neurofibromatosis
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 28, 2026, 9:46 AM EDT
Recruiting Phase 3 Interventional

Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)

NCT06891443
View directory record Official record
Conditions
Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Sensation Disorders, Vision Disorder, Neurological Manifestations, Eye Diseases, Hereditary, Eye Diseases, Eye Disorders Congenital, Retinal Disease
Interventions
sepofarsen, Placebo IVT
Drug · Other
Lead sponsor
Laboratoires Thea
Industry
Eligibility
6 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
San Francisco, California • Miami, Florida • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 28, 2026, 9:46 AM EDT
Active, not recruiting No phase listed Observational

Parental Decision-Making for Children With Relapsed Neuroblastoma

NCT02282735
View directory record Official record
Conditions
Relapsed Neuroblastoma
Interventions
Not listed
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 28, 2026, 9:46 AM EDT
Terminated Phase 2 Interventional Results available

Biochemotherapy With Temozolomide for Metastatic Melanoma

NCT00505635
View directory record Official record
Conditions
Melanoma
Interventions
Temozolomide, Velban, Cisplatin, Interleukin-2, Intron-A, Thalidomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 28, 2026, 9:46 AM EDT
Recruiting Phase 3 Interventional

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

NCT05549297
View directory record Official record
Conditions
Advanced Melanoma
Interventions
Tebentafusp, Tebentafusp with Pembrolizumab, Investigators Choice
Drug
Lead sponsor
Immunocore Ltd
Industry
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
25
States / cities
Phoenix, Arizona • Jacksonville, Florida • Orlando, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 28, 2026, 9:46 AM EDT
Completed Phase 1Phase 2 Interventional Results available

RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA

NCT01497808
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Ipilimumab, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 28, 2026, 9:46 AM EDT